Related Experiment Videos
Management of atrial tachyarrhythmias: benefits of pacemaker diagnostics
Laurent Fauchier1, Florent Briand, François Xavier Soto
1Department of Cardiology B, Centre Hospitalier Universitaire, Trousseau, 37044 Tours. lfau@med.univtours.fr
Insights
The Selection pacemaker's AF 1.0 function significantly improved atrial fibrillation (AF) management by providing crucial data, especially for asymptomatic patients. This diagnostic tool enabled personalized therapeutic adjustments, enhancing patient care.
Area of Science:
- Cardiology
- Biomedical Engineering
Background:
- Atrial fibrillation (AF) management presents challenges, particularly in identifying and treating asymptomatic episodes.
- Pacemaker diagnostic functions are evolving to provide more detailed insights into cardiac arrhythmias.
Purpose of the Study:
- To evaluate the clinical utility of the Vitatron Selection pacemaker's AF 1.0 diagnostic function in managing atrial fibrillation.
- To determine if AF 1.0 data influences therapeutic decisions in patients with AF and pacing indications.
Main Methods:
- Prospective multicenter study involving 40 patients with documented AF.
- Utilized the Selection pacemaker with AF 1.0 function to record AF burden, onset, duration, and other parameters for episodes >180 beats/min.
- Compared AF 1.0 data with patient symptoms and conventional assessments at 3- and 6-month follow-ups.
Main Results:
- AF recurrences were detected in 71% of follow-ups, with only 16% reported symptomatically.
- AF 1.0 data modified initial therapeutic changes in 61% of cases, influencing pacing parameters (56%), AF prevention algorithms (37%), and medical treatment (7%).
- Investigators found AF 1.0 useful in all patients, highlighting its value in managing asymptomatic AF.
Conclusions:
- The AF 1.0 function provides essential documentation of AF, particularly in asymptomatic individuals.
- This diagnostic capability allows for crucial, otherwise impossible, therapeutic adjustments in AF management.
- The Vitatron Selection pacemaker's AF 1.0 function demonstrates significant clinical benefits in optimizing patient care for atrial fibrillation.
Abstract:
The aim of this prospective multicenter study was to assess the clinical benefits of the Selection (Vitatron) pacemaker diagnostic functions (AF 1.0) in the management of AF. Forty patients (71 +/- 9 years of age), with documented AF and conventional pacing indications, received a Selection. The AF 1.0 function of the pacemaker was programmed to document the AF burden, onset, daily distribution, duration, premature atrial beats before onset, and mode of onset of the last 12 episodes for AF episodes exceeding 180 beats/min. By comparing patients' symptoms records, patient conventional assessment at follow-up and AF 1.0 data, the investigators evaluated the usefulness of AF 1.0 in AF management at 3- and 6-month follow-ups. Usefulness was defined as a change in arrhythmia management prompted by the disclosure of AF 1.0 data. AF recurrences were recorded in 71% of the follow-ups with symptoms reported by patients in only 16%. Thirty-nine percent of therapeutic changes based on conventional assessment were confirmed by AF 1.0 data, and in 61% of instances, the initial changes were modified by AF 1.0 data. Changes included pacing parameters in 56% of cases, AF prevention with pacing algorithms in 37%, and medical treatment in 7%. All investigators indicated that AF 1.0 was useful in all patients. The AF 1.0 diagnostic functions offered a unique documentation of AF in asymptomatic patients, and allowed therapeutic adjustments impossible otherwise.